Innovating Works

BUNDESINSTITUT FUR ARZNEIMITTEL UND MEDI...

Desconocido
QUANTUM: Quality Utility and Maturity Measured Developing a Data Quality and Utility Label for HealthData@E... BUNDESINSTITUT FUR ARZNEIMITTEL UND MEDIZINPRODUKTE participó en un HORIZON EUROPE: HORIZON-HLTH-2023-TOOL-05 Context: Data users (i.e., researchers, innovators, regulation agencies and policy-makers) need high-quality data. In HealthData@EU, data ho...
2023-12-11 - 2026-06-30 | Financiado
Real4Reg: Development, optimisation and implementation of artificial intelligence methods for real world data... BUNDESINSTITUT FUR ARZNEIMITTEL UND MEDIZINPRODUKTE tramitó un HORIZON EUROPE: HORIZON-HLTH-2022-TOOL-11 Real-world evidence derived from real-world data (RWD) has a promising role to inform regulatory decision-making. Based on highly relevant u...
2023-01-01 - 2026-12-31 | Financiado
REMEDI4ALL: BUILDING A SUSTAINABLE EUROPEAN INNOVATION PLATFORM TO ENHANCE THE REPURPOSING OF MEDICINES FOR ALL BUNDESINSTITUT FUR ARZNEIMITTEL UND MEDIZINPRODUKTE participó en un HORIZON EUROPE: HORIZON-HLTH-2021-DISEASE-04 REMEDI4ALL aims to establish Europe's leadership globally in the repurposing of medicines by creating a vibrant community of practice coveri...
2022-05-19 - 2027-08-31 | Financiado
X-eHealth: X eHealth eXchanging electronic Health Records in a commom framework BUNDESINSTITUT FUR ARZNEIMITTEL UND MEDIZINPRODUKTE participó en un H2020: H2020-SC1-DTH-2018-2020 X-eHealth’s project stands herein for a project of strategic relevance for tomorrow’s European eHealth Union. Assembling at the time of this...
2020-06-04 - 2022-11-30 | Financiado
HARMONY PLUS: HEALTHCARE ALLIANCE FOR RESOURCEFUL MEDICINES OFFENSIVE AGAINST NEOPLASMS IN HEMATOLOGY PLUS BUNDESINSTITUT FUR ARZNEIMITTEL UND MEDIZINPRODUKTE participó en un H2020: H2020-JTI-IMI2-2019-19-single-stage Haematological malignancies (HM), also known as blood cancers, are a heterogeneous and complex group of multicausal diseases that can’t be e...
2020-05-26 - 2024-03-31 | Financiado
UNICOM: Up scaling the global univocal identification of medicines BUNDESINSTITUT FUR ARZNEIMITTEL UND MEDIZINPRODUKTE participó en un H2020: H2020-SC1-DTH-2018-2020 This innovation action will give a powerful impulse to implementation of ISO IDMP (ID of Medicinal Products) standards in EU Member States d...
2019-11-11 - 2024-05-31 | Financiado
EJP RD: European Joint Programme on Rare Diseases BUNDESINSTITUT FUR ARZNEIMITTEL UND MEDIZINPRODUKTE participó en un H2020: H2020-SC1-BHC-2018-2020 As recognized by the Council Recommendation 2009/C 151/02, rare diseases (RD) are a prime example of a research area that can strongly profi...
2018-12-13 - 2024-08-31 | Financiado
STARS: Strengthening training of academia in regulatory sciences and supporting regulatory scientific advic... BUNDESINSTITUT FUR ARZNEIMITTEL UND MEDIZINPRODUKTE tramitó un H2020: H2020-SC1-BHC-2018-2020 Lack of specific relevant know-how in regulatory science delays the development of new treatment strategies or limits the chances that promi...
2018-11-20 - 2022-06-30 | Financiado
EUROoC: Interdisciplinary training network for advancing Organ on a chip technology in Europe BUNDESINSTITUT FUR ARZNEIMITTEL UND MEDIZINPRODUKTE participó en un H2020: H2020-MSCA-ITN-2018 EUROoC will create a trans-European network of industrially oriented specialists fully trained in development and application of the emergin...
2018-08-21 - 2023-05-31 | Financiado
HARMONY: Healthcare Alliance for Resourceful Medicines Offensive against Neoplasms in HematologY Sofia ref.... BUNDESINSTITUT FUR ARZNEIMITTEL UND MEDIZINPRODUKTE participó en un H2020: H2020-JTI-IMI2-2015-06-two-stage Despite significant recent progress in the field of hematological malignancies (HMs), with increasing survival rates and improvement in qual...
2016-12-22 - 2023-06-30 | Financiado
U-PGx: Ubiquitous Pharmacogenomics U PGx Making actionable pharmacogenomic data and effective treatment... BUNDESINSTITUT FUR ARZNEIMITTEL UND MEDIZINPRODUKTE participó en un H2020: H2020-PHC-2014-2015 Pharmacogenomics is the study of genetic variability affecting an individual’s response to a drug. Its use allows personalized medicine and...
2015-12-09 - 2021-12-31 | Financiado
PERMED: Personalized Medicine 2020 and beyond Preparing Europe for leading the global way PerMed BUNDESINSTITUT FUR ARZNEIMITTEL UND MEDIZINPRODUKTE participó en un FP7: The Health Directorate of the European Commission's DG Research and Innovation recently stated that Personalized Medicine is one of the most...
Financiado
GP-TCM: Good Practice in Traditional Chinese Medicine Research in the Post genomic Era BUNDESINSTITUT FUR ARZNEIMITTEL UND MEDIZINPRODUKTE participó en un FP7: In contrast to the reductionist approach of Western medicine that is based on modern anatomy, cell and molecular biology, Traditional Chines...
Financiado
InSPiRe: Innovative methodology for small populations research BUNDESINSTITUT FUR ARZNEIMITTEL UND MEDIZINPRODUKTE participó en un FP7: The HEALTH.2013.4.2-3 call identifies a need for new or improved statistical methodology for clinical trials for the efficient assessment of...
Financiado
* Datos extraídos de la documentos o webs disponibles en diferentes organismos públicos.